NASDAQ:CGIX - Cancer Genetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.03 +0.05 (+5.10 %)
(As of 05/27/2018 03:37 AM ET)
Previous Close$1.03
Today's Range$0.9813 - $1.04
52-Week Range$0.82 - $4.35
Volume137,294 shs
Average Volume220,771 shs
Market Capitalization$27.19 million
P/E Ratio-1.30
Dividend YieldN/A
Beta1.28

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics logoCancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.

Receive CGIX News and Ratings via Email

Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGIX
CUSIPN/A
Phone201-528-9200

Debt

Debt-to-Equity Ratio0.03
Current Ratio0.92
Quick Ratio0.92

Price-To-Earnings

Trailing P/E Ratio-1.30
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$29.12 million
Price / Sales0.98
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book1.43

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,880,000.00
Net Margins-52.87%
Return on Equity-77.26%
Return on Assets-38.54%

Miscellaneous

Employees245
Outstanding Shares27,750,000

Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How were Cancer Genetics' earnings last quarter?

Cancer Genetics, Inc. (NASDAQ:CGIX) issued its quarterly earnings results on Tuesday, May, 15th. The medical research company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.03. The medical research company earned $7.67 million during the quarter, compared to analyst estimates of $10.20 million. Cancer Genetics had a negative return on equity of 77.26% and a negative net margin of 52.87%. View Cancer Genetics' Earnings History.

What price target have analysts set for CGIX?

4 brokerages have issued 1-year price targets for Cancer Genetics' stock. Their predictions range from $6.00 to $6.00. On average, they expect Cancer Genetics' share price to reach $6.00 in the next year. View Analyst Ratings for Cancer Genetics.

What are Wall Street analysts saying about Cancer Genetics stock?

Here are some recent quotes from research analysts about Cancer Genetics stock:
  • 1. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (5/14/2018)
  • 2. Maxim Group analysts commented, "We are downgrading CGIX to Hold, from Buy and removing our price target following disappointing 4Q revenues, an increase in bad debt expense which was a surprise that leaves us with some concerns around the company’s ability to collect account receivables related to acquired testing platforms and/ or companies, and in our view, a lack of strategic direction of the company. 4Q17 revenue of $7.5M, up 4% y/y compared to the consensus estimate of $9.2M. Operating expenses in 4Q17 rose 82% and included $4.4M in bad debt expense." (4/3/2018)

Who are some of Cancer Genetics' key competitors?

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the folowing people:
  • Mr. John A. Roberts, Interim CEO & COO (Age 59)
  • Dr. Raju S. K. Chaganti, Founder & Director (Age 85)
  • Mr. Igor Gitelman CPA, MBA, Chief Accounting Officer (Age 42)
  • Mr. Cory Hickmon, VP of Bus. Devel. and Director of National Clinical Sales
  • Ms. Molly Lukes PHR, SHRM-CP, VP of HR

Has Cancer Genetics been receiving favorable news coverage?

Headlines about CGIX stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cancer Genetics earned a news impact score of 0.24 on Accern's scale. They also gave press coverage about the medical research company an impact score of 47.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Cancer Genetics' major shareholders?

Cancer Genetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.22%). Company insiders that own Cancer Genetics stock include Edward J Sitar, Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Institutional Ownership Trends for Cancer Genetics.

Which institutional investors are selling Cancer Genetics stock?

CGIX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Cancer Genetics.

How do I buy shares of Cancer Genetics?

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $1.03.

How big of a company is Cancer Genetics?

Cancer Genetics has a market capitalization of $27.19 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]


MarketBeat Community Rating for Cancer Genetics (CGIX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cancer Genetics (NASDAQ:CGIX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Cancer Genetics in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 482.52%. The high price target for CGIX is $6.00 and the low price target for CGIX is $6.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.252.252.752.67
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$6.00$6.00
Price Target Upside: 482.52% upside531.58% upside233.33% upside110.53% upside

Cancer Genetics (NASDAQ:CGIX) Consensus Price Target History

Price Target History for Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics (NASDAQ:CGIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2018Dawson JamesDowngradeBuy ➝ NeutralHighView Rating Details
4/3/2018Maxim GroupDowngradeBuy ➝ Hold$6.00LowView Rating Details
2/6/2018HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
6/26/2017BenchmarkInitiated CoverageSpeculative Buy$3.85 ➝ $6.00HighView Rating Details
9/26/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Cancer Genetics (NASDAQ:CGIX) Earnings History and Estimates Chart

Earnings by Quarter for Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics (NASDAQ:CGIX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.43 EPS

Cancer Genetics (NASDAQ CGIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018Q1 2018($0.13)($0.16)$10.20 million$7.67 millionViewListenView Earnings Details
4/2/2018Q4 2017($0.35)$9.45 million$7.50 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.13)($0.16)$7.96 million$8.03 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.16)($0.16)$7.97 million$6.60 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.11)$7.62 million$7.00 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.22)($0.15)$7.10 million$7.23 millionViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.2280)$6.93 million$6.80 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.28)$6.50 million$7.00 millionViewN/AView Earnings Details
5/10/2016Q1($0.43)($0.39)$6.95 million$6.10 millionViewListenView Earnings Details
3/10/2016Q415($0.46)($0.48)$7.00 million$5.50 millionViewListenView Earnings Details
11/10/2015Q315($0.49)($0.56)$5.13 million$4.00 millionViewListenView Earnings Details
8/11/2015Q215($0.50)($0.51)$4.67 million$4.20 millionViewListenView Earnings Details
5/12/2015Q115($0.54)($0.43)$3.91 million$4.40 millionViewListenView Earnings Details
3/12/2015Q414($0.52)($0.49)$3.70 million$4.00 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.51)($0.41)$3.11 million$3.22 millionViewN/AView Earnings Details
8/14/2014Q214($0.39)($0.50)$2.13 million$3.20 millionViewN/AView Earnings Details
5/15/2014Q114($0.29)($0.27)$2.17 million$1.40 millionViewN/AView Earnings Details
3/26/2014Q4 13($0.36)($0.37)$1.95 million$1.90 millionViewN/AView Earnings Details
11/13/2013Q313($0.71)($0.61)$1.60 million$1.70 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.53)($0.57)$1.50 million$1.83 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cancer Genetics (NASDAQ:CGIX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cancer Genetics (NASDAQ CGIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.30%
Institutional Ownership Percentage: 17.22%
Insider Trading History for Cancer Genetics (NASDAQ:CGIX)
Institutional Ownership by Quarter for Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics (NASDAQ CGIX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017John A RobertsCOOBuy12,200$2.00$24,400.0012,200View SEC Filing  
12/8/2017John PappajohnDirectorBuy150,000$1.86$279,000.002,781,204View SEC Filing  
8/18/2017John PappajohnDirectorBuy86,185$3.24$279,239.402,608,704View SEC Filing  
8/17/2017John PappajohnDirectorBuy86,185$3.24$279,239.402,608,704View SEC Filing  
6/12/2017John PappajohnDirectorBuy100,000$3.75$375,000.002,542,519View SEC Filing  
5/25/2017Igor GitelmanInsiderBuy937$3.95$3,701.15937View SEC Filing  
5/23/2017Igor GitelmanInsiderSell937$4.02$3,766.74937View SEC Filing  
5/16/2017Geoffrey E HarrisDirectorBuy2,500$3.75$9,375.0022,500View SEC Filing  
12/14/2016Geoffrey E HarrisDirectorBuy2,500$1.50$3,750.0020,000View SEC Filing  
11/28/2016John PappajohnDirectorBuy100,000$1.45$145,000.002,420,709View SEC Filing  
11/16/2016Edward J SitarCFOSell3,333$1.56$5,199.4814,167View SEC Filing  
11/14/2016John PappajohnDirectorBuy31,100$1.48$46,028.002,320,709View SEC Filing  
8/16/2016John PappajohnDirectorBuy45,000$2.29$103,050.002,287,109View SEC Filing  
8/15/2016John PappajohnDirectorBuy147,500$2.16$318,600.002,162,387View SEC Filing  
3/17/2016John PappajohnDirectorBuy50,000$2.64$132,000.001,771,789View SEC Filing  
3/17/2016Panna SharmaCEOBuy1,500$2.59$3,885.00152,000View SEC Filing  
3/16/2016John PappajohnDirectorBuy100,000$2.53$253,000.001,711,210View SEC Filing  
3/15/2016Panna SharmaCEOBuy1,000$2.56$2,560.00151,000View SEC Filing  
8/27/2015John PappajohnDirectorBuy5,000$9.61$48,050.001,519,289View SEC Filing  
6/25/2015Raju S.K. ChagantiDirectorSell5,296$12.00$63,552.00View SEC Filing  
6/12/2015Raju S.K. ChagantiDirectorSell7,000$12.01$84,070.00View SEC Filing  
6/11/2015Raju S.K. ChagantiDirectorSell46,454$12.03$558,841.62View SEC Filing  
6/8/2015Raju S.K. ChagantiDirectorSell24,583$12.03$295,733.49View SEC Filing  
5/14/2015John PappajohnDirectorBuy5,000$10.74$53,700.00View SEC Filing  
3/17/2015John PappajohnDirectorBuy50,000$7.36$368,000.00View SEC Filing  
3/16/2015Edward J SitarCFOBuy1,000$6.99$6,990.00View SEC Filing  
12/16/2014John PappajohnDirectorBuy5,589$6.20$34,651.80View SEC Filing  
12/15/2014John PappajohnDirectorBuy3,634$6.14$22,312.76View SEC Filing  
12/11/2014John PappajohnDirectorBuy27,087$6.03$163,334.61View SEC Filing  
12/10/2014John PappajohnDirectorBuy5,773$5.96$34,407.08View SEC Filing  
12/9/2014John PappajohnDirectorBuy39,686$5.35$212,320.10View SEC Filing  
5/21/2014Edward SitarCFOBuy1,000$10.67$10,670.001,000View SEC Filing  
5/21/2014John PappajohnDirectorBuy50,000$10.31$515,500.001,313,232View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cancer Genetics (NASDAQ CGIX) News Headlines

Source:
DateHeadline
CGIX $100,000 Threshold: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Cancer Genetics, Inc. InvestorsCGIX $100,000 Threshold: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Cancer Genetics, Inc. Investors
feeds.benzinga.com - May 24 at 9:33 PM
Head to Head Review: Cancer Genetics (CGIX) vs. Foundation Medicine (FMI)Head to Head Review: Cancer Genetics (CGIX) vs. Foundation Medicine (FMI)
www.americanbankingnews.com - May 24 at 5:31 PM
Edited Transcript of CGIX earnings conference call or presentation 15-May-18 12:30pm GMTEdited Transcript of CGIX earnings conference call or presentation 15-May-18 12:30pm GMT
finance.yahoo.com - May 23 at 8:15 AM
New Cancer Treatments Lie Hidden Under Mountains of PaperworkNew Cancer Treatments Lie Hidden Under Mountains of Paperwork
www.nytimes.com - May 22 at 8:16 AM
Contrasting Cancer Genetics (CGIX) & Fulgent Genetics (FLGT)Contrasting Cancer Genetics (CGIX) & Fulgent Genetics (FLGT)
www.americanbankingnews.com - May 21 at 11:19 AM
CGIX DEADLINE: Pawar Law Reminds Investors of Important June 4, 2018 Lead Plaintiff Deadline in Class ActionCGIX DEADLINE: Pawar Law Reminds Investors of Important June 4, 2018 Lead Plaintiff Deadline in Class Action
finance.yahoo.com - May 17 at 7:00 PM
Cancer Genetics (CGIX) Announces  Earnings ResultsCancer Genetics (CGIX) Announces Earnings Results
www.americanbankingnews.com - May 16 at 2:36 PM
Form 8-K CANCER GENETICS, INC For: May 15Form 8-K CANCER GENETICS, INC For: May 15
www.streetinsider.com - May 15 at 5:53 PM
Earnings Reaction History: Cancer Genetics, Inc., 80.0% Follow-Through Indicator, 8.9% SensitiveEarnings Reaction History: Cancer Genetics, Inc., 80.0% Follow-Through Indicator, 8.9% Sensitive
www.nasdaq.com - May 15 at 5:53 PM
CGIX DEADLINE: Rosen Law Firm Reminds Cancer Genetics, Inc. Investors of Important Deadline in First Filed Case ...CGIX DEADLINE: Rosen Law Firm Reminds Cancer Genetics, Inc. Investors of Important Deadline in First Filed Case ...
globenewswire.com - May 15 at 5:53 PM
Cancer Genetics (CGIX) CEO Jay Roberts on Q1 2018 Results - Earnings Call TranscriptCancer Genetics' (CGIX) CEO Jay Roberts on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 5:53 PM
DEADLINE ALERT: Shareholder Class Action Filed Against Cancer Genetics, Inc. - CGIXDEADLINE ALERT: Shareholder Class Action Filed Against Cancer Genetics, Inc. - CGIX
finance.yahoo.com - May 15 at 5:52 PM
CGIX DEADLINE: Rosen Law Firm Reminds Cancer Genetics, Inc. Investors of Important Deadline in First Filed Case – CGIXCGIX DEADLINE: Rosen Law Firm Reminds Cancer Genetics, Inc. Investors of Important Deadline in First Filed Case – CGIX
finance.yahoo.com - May 15 at 5:52 PM
Cancer Genetics misses by $0.03, misses on revenueCancer Genetics misses by $0.03, misses on revenue
seekingalpha.com - May 15 at 8:20 AM
Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business UpdatesCancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates
finance.yahoo.com - May 15 at 8:20 AM
Cancer Genetics: 1Q Earnings SnapshotCancer Genetics: 1Q Earnings Snapshot
finance.yahoo.com - May 15 at 8:20 AM
Zacks Investment Research Upgrades Cancer Genetics (CGIX) to "Hold"Zacks Investment Research Upgrades Cancer Genetics (CGIX) to "Hold"
www.americanbankingnews.com - May 14 at 8:10 PM
Cancer Genetics (CGIX) Set to Announce Quarterly Earnings on TuesdayCancer Genetics (CGIX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 12 at 8:32 PM
Fulgent Genetics (FLGT) & Cancer Genetics (CGIX) Financial SurveyFulgent Genetics (FLGT) & Cancer Genetics (CGIX) Financial Survey
www.americanbankingnews.com - May 12 at 3:28 PM
INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 10 at 6:04 PM
Cancer Genetics to Report First Quarter 2018 Financial Results on May 15, 2018Cancer Genetics to Report First Quarter 2018 Financial Results on May 15, 2018
finance.yahoo.com - May 10 at 6:04 PM
Head to Head Analysis: Cancer Genetics (CGIX) and Genomic Health (GHDX)Head to Head Analysis: Cancer Genetics (CGIX) and Genomic Health (GHDX)
www.americanbankingnews.com - May 9 at 7:29 PM
Deadline Alert for Cancer Genetics, Inc. Shareholders in Class Action Lawsuit - CGIXDeadline Alert for Cancer Genetics, Inc. Shareholders in Class Action Lawsuit - CGIX
finance.yahoo.com - May 9 at 8:13 AM
CANCER GENETICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed against Cancer Genetics, Inc. in the United States District Court for the District of New JerseyCANCER GENETICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed against Cancer Genetics, Inc. in the United States District Court for the District of New Jersey
finance.yahoo.com - May 8 at 5:45 PM
PAWAR LAW: Important June 4, 2018 Lead Plaintiff Deadline in Cancer Genetics, Inc. Class Action- CGIXPAWAR LAW: Important June 4, 2018 Lead Plaintiff Deadline in Cancer Genetics, Inc. Class Action- CGIX
finance.yahoo.com - May 8 at 5:45 PM
CANCER GENETICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed against Cancer Genetics, Inc. in the United States District Court for the District of New JerseyCANCER GENETICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed against Cancer Genetics, Inc. in the United States District Court for the District of New Jersey
feeds.benzinga.com - May 8 at 12:55 PM
Lawsuit for Investors in Cancer Genetics, Inc. (NASDAQ: CGIX) with Substantial Financial Losses Announced by Shareholders FoundationLawsuit for Investors in Cancer Genetics, Inc. (NASDAQ: CGIX) with Substantial Financial Losses Announced by Shareholders Foundation
finance.yahoo.com - May 8 at 8:11 AM
Cancer Genetics, Inc. (CGIX) Given Consensus Recommendation of "Hold" by BrokeragesCancer Genetics, Inc. (CGIX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 6 at 10:19 AM
Cancer Genetics (CGIX) Stock Rating Upgraded by ValuEngineCancer Genetics (CGIX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM
Cancer Genetics (CGIX) Stock Rating Upgraded by Zacks Investment ResearchCancer Genetics (CGIX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 3 at 8:24 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) & Lead Plaintiff Deadline - June 4, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) & Lead Plaintiff Deadline - June 4, 2018
finance.yahoo.com - May 3 at 5:29 PM
EQUITY NOTICE: Rosen Law Firm Files Securities Class Action Lawsuit Against Cancer Genetics, Inc. - CGIXEQUITY NOTICE: Rosen Law Firm Files Securities Class Action Lawsuit Against Cancer Genetics, Inc. - CGIX
finance.yahoo.com - May 1 at 5:21 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – CGIXSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – CGIX
finance.yahoo.com - April 28 at 8:23 AM
RM LAW Announces Class Action Lawsuit Against Cancer Genetics, Inc.RM LAW Announces Class Action Lawsuit Against Cancer Genetics, Inc.
www.prnewswire.com - April 27 at 8:13 PM
Cancer Genetics (CGIX) Reports Sale of India Operations to REPROCELL Inc. for $1.9MCancer Genetics (CGIX) Reports Sale of India Operations to REPROCELL Inc. for $1.9M
www.streetinsider.com - April 27 at 5:18 PM
Cancer Genetics Announces Sale of India Operations to REPROCELL IncorporatedCancer Genetics Announces Sale of India Operations to REPROCELL Incorporated
finance.yahoo.com - April 27 at 5:18 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) & Lead Plaintiff Deadline: June 4, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) & Lead Plaintiff Deadline: June 4, 2018
finance.yahoo.com - April 27 at 5:18 PM
CGIX LOSS NOTICE: Rosen Law Firm Reminds Cancer Genetics, Inc. Investors of Important Deadline in First Filed CaseCGIX LOSS NOTICE: Rosen Law Firm Reminds Cancer Genetics, Inc. Investors of Important Deadline in First Filed Case
finance.yahoo.com - April 21 at 5:19 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - CGIXSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - CGIX
finance.yahoo.com - April 21 at 8:15 AM
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Cancer Genetics, Inc. - CGIXSHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Cancer Genetics, Inc. - CGIX
finance.yahoo.com - April 20 at 5:26 PM
Cancer Genetics (CGIX) Research Coverage Started at Dawson JamesCancer Genetics (CGIX) Research Coverage Started at Dawson James
www.americanbankingnews.com - April 20 at 3:01 PM
Pomerantz Law Firm Announces the Filing of a Class Action against Cancer Genetics, Inc. and Certain Officers – CGIXPomerantz Law Firm Announces the Filing of a Class Action against Cancer Genetics, Inc. and Certain Officers – CGIX
finance.yahoo.com - April 18 at 5:49 PM
SHAREHOLDER INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. and Encourages Investors with Losses to Contact The FirmSHAREHOLDER INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. and Encourages Investors with Losses to Contact The Firm
finance.yahoo.com - April 17 at 8:22 AM
Today’s Research Reports on Stocks to Watch: Celldex Therapeutics and Cancer GeneticsToday’s Research Reports on Stocks to Watch: Celldex Therapeutics and Cancer Genetics
finance.yahoo.com - April 17 at 8:22 AM
FDA Gives Thumbs Up to Cancer Genetics TOO Diagnostic TestFDA Gives Thumbs Up to Cancer Genetics' TOO Diagnostic Test
www.baystreet.ca - April 16 at 5:30 PM
Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) ClearanceCancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance
finance.yahoo.com - April 16 at 8:11 AM
Critical Contrast: Miragen Therapeutics (MGEN) versus Cancer Genetics (CGIX)Critical Contrast: Miragen Therapeutics (MGEN) versus Cancer Genetics (CGIX)
www.americanbankingnews.com - April 15 at 7:19 PM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. and Encourages Investors with Losses to Contact The FirmONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. and Encourages Investors with Losses to Contact The Firm
finance.yahoo.com - April 12 at 5:44 PM
Head to Head Review: Natera (NTRA) and Cancer Genetics (CGIX)Head to Head Review: Natera (NTRA) and Cancer Genetics (CGIX)
www.americanbankingnews.com - April 12 at 9:09 AM
Zacks Investment Research Downgrades Cancer Genetics (CGIX) to SellZacks Investment Research Downgrades Cancer Genetics (CGIX) to Sell
www.americanbankingnews.com - April 11 at 8:26 PM

SEC Filings

Cancer Genetics (NASDAQ:CGIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cancer Genetics (NASDAQ:CGIX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cancer Genetics (NASDAQ CGIX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.